Aradigm Corporation
Records under this name other than patents Aradigm Corporation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,268,347 | Dual action, inhaled formulations providing both an immediate and sustained release profile Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,844,548 | Liposomal ciprofloxacin formulations with encapsulated ciprofloxacin nanocrystals Formerly held Lapsed on the fee record Ended Dec 19, 2025 · From the USPTO record | Lapsed on the fee record | Ended Dec 19, 2025 | From the USPTO record |
| US 11,026,941 | Concentrated, inhalable ciprofloxacin formulation Formerly held Lapsed on the fee record Ended Jun 8, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jun 8, 2025 | From the USPTO record |
| US 8,414,915 | Dual action, inhaled formulations providing both an immediate and sustained release profile Formerly held Lapsed on the fee record Ended Apr 9, 2025 · From the USPTO record | Lapsed on the fee record | Ended Apr 9, 2025 | From the USPTO record |
| US 9,545,401 | Concentrated, inhalable ciprofloxacin formulation Formerly held Lapsed on the fee record Ended Jan 17, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jan 17, 2025 | From the USPTO record |
| US 9,532,986 | Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria Formerly held Lapsed on the fee record Ended Jan 3, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jan 3, 2025 | From the USPTO record |
| US 8,119,156 | Dual action, inhaled formulations providing both an immediate and sustained release profile Formerly held Lapsed on the fee record Ended Feb 21, 2024 · From the USPTO record | Lapsed on the fee record | Ended Feb 21, 2024 | From the USPTO record |
| US 9,259,424 | Concentrated, inhalable antibiotic formulation Formerly held Lapsed on the fee record Ended Feb 16, 2024 · From the USPTO record | Lapsed on the fee record | Ended Feb 16, 2024 | From the USPTO record |
| US 8,256,433 | Systems and methods for effecting cessation of tobacco use Term ended Term ended Jan 7, 2024 · From the USPTO record | Term ended | Term ended Jan 7, 2024 | From the USPTO record |
| US 8,071,127 | Dual action, inhaled formulations providing both an immediate and sustained release profile Formerly held Lapsed on the fee record Ended Dec 6, 2023 · From the USPTO record | Lapsed on the fee record | Ended Dec 6, 2023 | From the USPTO record |